Go Pro
→ Elon’s AI Phone is coming (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Electromed, Inc. stock logo
ELMD
Electromed
$27.57
$35.33
$23.01
▼
$47.40
$230.65M0.4678,443 shs71,815 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$71.94
-0.6%		$64.07
$23.47
▼
$77.00
$231.95M0.0675,954 shs96,359 shs
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.63
-4.1%		$1.41
$0.70
▼
$2.59
$76.72M1.121.47 million shs765,004 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
-1.7%		$4.50
$1.17
▼
$7.08
$293.31M1.4221,997 shs317,965 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Electromed, Inc. stock logo
ELMD
Electromed
0.00%+5.43%-31.57%-31.16%+15.45%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-0.65%+0.13%+7.60%+10.15%+112.15%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-4.12%+5.16%+30.40%+75.27%+32.52%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-1.74%-1.10%+3.20%+1.35%-33.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Electromed, Inc. stock logo
ELMD
Electromed
$27.57
$35.33
$23.01
▼
$47.40
$230.65M0.4678,443 shs71,815 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$71.94
-0.6%		$64.07
$23.47
▼
$77.00
$231.95M0.0675,954 shs96,359 shs
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.63
-4.1%		$1.41
$0.70
▼
$2.59
$76.72M1.121.47 million shs765,004 shs
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$4.51
-1.7%		$4.50
$1.17
▼
$7.08
$293.31M1.4221,997 shs317,965 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Electromed, Inc. stock logo
ELMD
Electromed
0.00%+5.43%-31.57%-31.16%+15.45%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-0.65%+0.13%+7.60%+10.15%+112.15%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-4.12%+5.16%+30.40%+75.27%+32.52%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-1.74%-1.10%+3.20%+1.35%-33.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Electromed, Inc. stock logo
ELMD
Electromed
2.75
Moderate Buy$43.7558.69% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
3.00
Buy$74.002.86% Upside
RenovoRx, Inc. stock logo
RNXT
RenovoRx
2.75
Moderate Buy$8.50421.47% Upside
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
1.86
Reduce$5.1714.63% Upside

Current Analyst Ratings Breakdown

Latest RNXT, TMCI, PDEX, and ELMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
9/15/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/11/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$70.00 ➝ $74.00
9/4/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
9/2/2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/31/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/26/2026
Electromed, Inc. stock logo
ELMD
Electromed
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$50.00
8/26/2026
Electromed, Inc. stock logo
ELMD
Electromed
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$36.00 ➝ $47.00
8/24/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
8/18/2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/14/2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Electromed, Inc. stock logo
ELMD
Electromed
$73.78M3.13$0.67 per share41.36$5.10 per share5.41
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$77.55M2.97$3.88 per share18.55$14.92 per share4.82
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.12M65.68N/AN/A$0.15 per share10.87
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
$205.31M1.43N/AN/A$1.37 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Electromed, Inc. stock logo
ELMD
Electromed
$5.15M$1.3136.76N/AN/A11.34%15.71%13.37%N/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$13.66M$4.1317.4221.41N/A17.62%25.13%16.02%10/29/2026 (Estimated)
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$11.17M-$0.31N/AN/AN/A-621.71%-135.11%-101.91%11/12/2026 (Estimated)
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$59M-$0.93N/AN/AN/A-28.99%-71.37%-30.49%11/5/2026 (Estimated)

Latest RNXT, TMCI, PDEX, and ELMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q4 2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.67$0.87+$0.20$0.87$19.20 million$20.41 million
8/12/2026Q2 2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$0.0725-$0.05+$0.0225-$0.06$0.70 million$0.91 million
8/7/2026Q2 2026
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
-$0.2980-$0.24+$0.0580-$0.24$44.02 million$45.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Electromed, Inc. stock logo
ELMD
Electromed
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/AN/AN/AN/AN/A
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Electromed, Inc. stock logo
ELMD
Electromed
N/A
5.10
4.74
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.28
4.10
2.45
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/A
5.74
5.53
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
0.83
2.90
1.95

Institutional Ownership

CompanyInstitutional Ownership
Electromed, Inc. stock logo
ELMD
Electromed
40.82%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
3.10%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
84.08%

Insider Ownership

CompanyInsider Ownership
Electromed, Inc. stock logo
ELMD
Electromed
10.50%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
45.90%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
9.40%
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
23.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Electromed, Inc. stock logo
ELMD
Electromed
1978.37 million7.36 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2063.20 million1.73 millionNot Optionable
RenovoRx, Inc. stock logo
RNXT
RenovoRx
1745.13 million40.89 millionNot Optionable
Treace Medical Concepts, Inc. stock logo
TMCI
Treace Medical Concepts
45065.04 million49.80 millionOptionable

Recent News About These Companies

Critical Comparison: Treace Medical Concepts (NASDAQ:TMCI) versus TransMedics Group (NASDAQ:TMDX)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044522
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
September 22 at 10:51 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/treace-medical-tmci-reports-five-year-bunion-results-can-evidence-drive-adoption-1840580/
Analyzing LogicMark (OTCMKTS:LGMKD) and Treace Medical Concepts (NASDAQ:TMCI)
September 21 at 8:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037138
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure
September 18, 2026  |  marketscreener.comM
Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...
September 18, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69614222-treace-medical-concepts-inc-treace-announces-results-of-three-clinical-studies-including-the-milestone-5-year-align3d-study-demonstrating-sustained-399.htm
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting
September 17, 2026  |  quiverquant.comQ
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3364415/0/en/treace-announces-results-of-three-clinical-studies-including-the-milestone-5-year-align3d-study-demonstrating-sustained-positive-outcomes-of-the-lapiplasty-procedure.html
Treace Highlights Foot & Ankle Portfolio Updates At 2026 AOFAS Annual Meeting
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691340/treace-highlights-foot-ankle-portfolio-updates-at-2026-aofas-annual-meeting.aspx
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026
September 15, 2026  |  quiverquant.comQ
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362722/0/en/treace-highlights-product-innovations-and-clinical-data-across-its-expanding-foot-ankle-portfolio-at-the-2026-aofas-annual-meeting.html
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-treace-medical-concepts-inc-tmci-2026-09-06/
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-treace-medical-concepts-inc-nasdaq-tmci-given-consensus-recommendation-of-reduce-by-analysts-2026-09-05/
Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-431-million-stock-holdings-in-treace-medical-concepts-inc-tmci-2026-08-29/
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tmci-insider-buying-and-selling-2026-08-25/
Treace Medical Concepts Earnings Call Signals Cautious Rebound
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/treace-medical-concepts-earnings-call-signals-cautious-rebound?utm_source=marketbeat.com&utm_medium=referral
Treace Medical (TMCI) Q2 2026 Earnings Call Transcript
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-tmci-q2-2026-135838195.html
Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary
August 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/treace-medical-concepts-inc-q2-211202340.html
Treace Medical Concepts: Q2 Earnings Snapshot
August 7, 2026  |  seattlepi.comS
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933135-treace-medical-concepts-inc-tmci-q2-2026-earnings-call-transcript
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970789/treace-medical-concepts-tmci-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970789
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341035/0/en/treace-medical-concepts-reports-second-quarter-2026-financial-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Electromed stock logo

Electromed NYSE:ELMD

$27.57 0.00 (0.00%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$27.64 +0.07 (+0.24%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$71.94 -0.47 (-0.65%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$72.01 +0.07 (+0.10%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

RenovoRx stock logo

RenovoRx NASDAQ:RNXT

$1.63 -0.07 (-4.12%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.56 -0.06 (-3.99%)
As of 07:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Treace Medical Concepts stock logo

Treace Medical Concepts NASDAQ:TMCI

$4.51 -0.08 (-1.74%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$4.40 -0.11 (-2.33%)
As of 07:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas